Novel Salmonella Vaccine Shows Promise in Clinical Trial

The investigational Trivalent Salmonella Conjugate Vaccine (TSCV) represents a significant advancement in combating typhoid fever and non-typhoidal Salmonella infections. These infections pose a substantial threat, particularly in sub-Saharan Africa, where they contribute to high rates of childhood illness and mortality.

The TSCV vaccine leverages sugar molecules from Salmonella Typhi bacteria (typhoid fever) and two common serotypes of invasive non-typhoidal Salmonella enterica, which are frequently implicated in U.S. outbreaks linked to contaminated poultry, eggs, and produce. The combination of these components aims to provide broad protection against major invasive Salmonella pathogens.

In the Phase 1 trial, 22 healthy adults received either a low dose (6.25 µg), a high dose (12.5 µg) of the vaccine, or a placebo. The results indicated that the vaccine was well-tolerated, with only mild injection site discomfort reported. More importantly, all vaccinated participants developed strong immune responses to the three targeted Salmonella strains, while placebo recipients did not. This immune response also involved white blood cells, suggesting potential for both localized and systemic protection against Salmonella.

The study also noted that some participants showed pre-existing Salmonella antibodies, likely from prior exposure through foodborne sources, which may enhance vaccine-induced immunity. This highlights the potential for the vaccine to be particularly effective in regions where Salmonella exposure is common.

Developed in collaboration with Bharat Biotech International Ltd., TSCV builds on the World Health Organization (WHO)-prequalified Typbar TCV platform. The next steps involve further trials, including studies in young children, who are the most vulnerable population.

It is a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella (iNTS) infections.

The vaccine combines sugar molecules from Salmonella Typhi bacteria and two common serotypes of invasive non-typhoidal Salmonella enterica, linked to proteins that enhance the body’s immune recognition.

The vaccine was safe and well-tolerated, with all vaccinated participants developing strong immune responses to the targeted Salmonella strains.

The vaccine was developed jointly by the University of Maryland’s Center for Vaccine Development and Global Health (CVD) and Bharat Biotech International Limited.

Do you think this vaccine will be a game-changer in combating typhoid and Salmonella infections? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!